Enlivex_
Stock Overview
About
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Company Details
Frequently Asked Questions
What does Enlivex do?
Enlivex is a company in the biotechnology industry. Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002),
When was Enlivex founded?
Enlivex was founded in , making it 21 years old.
Where is Enlivex headquartered?
Enlivex is headquartered in Ness Ziona.
Is Enlivex publicly traded?
Yes, Enlivex is a publicly traded company with the stock ticker symbol ENLV.
